In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Carl-Åke Carlsson CEO at Xellia Pharmaceuticals. Like celebrated “one-club” football stars like Leo Messi at Barcelona, Alessandro Del Piero at Juventus and Steven Gerrard at Liverpool… Carl-Åke has been with Xellia since 1988. A pharmaceutical leader known for his class and commercial acumen, Carl‑Åke started in a finance position. He was soon diversifying into other areas and running various divisions before rising to the top as global CEO of a business that employs 1,800 people.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl-Åke Carlsson, covering Xellia’s journey from an API supplier to a global specialty pharma company known for novel anti-infective, life-saving medicines. Carl‑Åke speaks about his journey from his position in finance to CEO and the transformation of Xellia as a company over the years, offering advice and insight from his experiences. He explains how he has created and scaled a world-class culture using internal, cross-functional “transformers” to assist in upholding values internally and externally. He speaks about the origins of the industry-renowned DCAT and CPhI Xellia parties. And lastly, he announces some exciting news about Xellia and their plans for expansion.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.